Oxidized Phospholipid Biomarkers for Cardiovascular Disease and Drug Development

Kleanthi Diagnostics develops and licenses diagnostic assays and research tools for measuring oxidized phospholipids (OxPL), important mediators of vascular inflammation and atherosclerotic cardiovascular disease.

Founded by Sotirios Tsimikas, MD, and Joseph L. Witztum, MD, Kleanthi builds on decades of basic, translational, and clinical research defining the biology of oxidation-specific epitopes, the E06 monoclonal antibody, lipoprotein(a) [Lp(a)], and the OxPL-apoB and OxPL-apo(a) biomarkers.

Our technology is used across the spectrum from clinical cardiovascular testing to pharmaceutical research and clinical trials.

Clinical Testing
OxPL-apoB testing is available through licensed clinical laboratory partners.

Pharmaceutical Research
Validated OxPL-apoB and OxPL-apo(a) assays are available for clinical trials and therapeutic-development programs.

Research Tools
E06 and related reagents enable investigation of oxidized phospholipids, inflammation, and oxidation-specific epitopes.

From biological discovery to clinical application.